Primary resistance to imatinib in Fip1-like 1-platelet-derived growth factor receptor alpha-positive eosinophilic leukemia.
Simon
Dagmar
D
Salemi
Souzan
S
Yousefi
Shida
S
Simon
Hans-Uwe
HU
D000595:Amino Acid Sequence; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001483:Base Sequence; D001549:Benzamides; D002908:Chronic Disease; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D006801:Humans; D017681:Hypereosinophilic Syndrome / Q000188:drug therapy* / Q000276:immunology* / Q000378:metabolism; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000096:biosynthesis* / Q000235:genetics; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000502:physiology*; D039221:mRNA Cleavage and Polyadenylation Factors / Q000096:biosynthesis* / Q000235:genetics
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001549:Benzamides; C479818:FIP1L1 protein, human; D010879:Piperazines; D011743:Pyrimidines; D011993:Recombinant Fusion Proteins; D039221:mRNA Cleavage and Polyadenylation Factors; D000068877:Imatinib Mesylate; C434107:mepolizumab; D020796:Receptor, Platelet-Derived Growth Factor alpha